

# Arul M Chinnaiyan

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1793766/arul-m-chinnaiyan-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

512  
papers

86,873  
citations

136  
h-index

289  
g-index

538  
ext. papers

100,133  
ext. citations

13.8  
avg, IF

7.7  
L-index

#	Paper	IF	Citations
512	Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. <i>Science</i> , <b>2005</b> , 310, 644-8	33.3	3022
511	FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. <i>Cell</i> , <b>1996</b> , 85, 817-27	56.2	2715
510	ONCOMINE: a cancer microarray database and integrated data-mining platform. <i>Neoplasia</i> , <b>2004</b> , 6, 1-6	6.4	2548
509	FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. <i>Cell</i> , <b>1995</b> , 81, 505-12	56.2	2110
508	The polycomb group protein EZH2 is involved in progression of prostate cancer. <i>Nature</i> , <b>2002</b> , 419, 624-9	30.4	2085
507	Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. <i>Genes and Development</i> , <b>2007</b> , 21, 2747-61	12.6	1938
506	The landscape of long noncoding RNAs in the human transcriptome. <i>Nature Genetics</i> , <b>2015</b> , 47, 199-208	36.3	1789
505	Integrative clinical genomics of advanced prostate cancer. <i>Cell</i> , <b>2015</b> , 161, 1215-1228	56.2	1765
504	The mutational landscape of lethal castration-resistant prostate cancer. <i>Nature</i> , <b>2012</b> , 487, 239-43	50.4	1708
503	Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. <i>Nature</i> , <b>2009</b> , 457, 910-4	50.4	1636
502	Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. <i>Neoplasia</i> , <b>2007</b> , 9, 166-80	6.4	1537
501	TEAD mediates YAP-dependent gene induction and growth control. <i>Genes and Development</i> , <b>2008</b> , 22, 1962-71	12.6	1534
500	The receptor for the cytotoxic ligand TRAIL. <i>Science</i> , <b>1997</b> , 276, 111-3	33.3	1514
499	Delineation of prognostic biomarkers in prostate cancer. <i>Nature</i> , <b>2001</b> , 412, 822-6	50.4	1402
498	The emergence of lncRNAs in cancer biology. <i>Cancer Discovery</i> , <b>2011</b> , 1, 391-407	24.4	1384
497	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 1697-708	59.2	1345
496	EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2003</b> , 100, 11606-11	11.5	1295

495	Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. <i>Science</i> , <b>2008</b> , 322, 1695-9	33.3	888
494	Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. <i>Nature Biotechnology</i> , <b>2011</b> , 29, 742-9	44.5	824
493	Development of human protein reference database as an initial platform for approaching systems biology in humans. <i>Genome Research</i> , <b>2003</b> , 13, 2363-71	9.7	823
492	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 443-53	59.2	791
491	Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2004</b> , 101, 9309-14	11.5	790
490	Activating ESR1 mutations in hormone-resistant metastatic breast cancer. <i>Nature Genetics</i> , <b>2013</b> , 45, 1446-51	36.3	742
489	Integrative molecular concept modeling of prostate cancer progression. <i>Nature Genetics</i> , <b>2007</b> , 39, 41-51	36.3	734
488	Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. <i>Cancer Research</i> , <b>2004</b> , 64, 9209-16	10.1	712
487	Transcriptome sequencing to detect gene fusions in cancer. <i>Nature</i> , <b>2009</b> , 458, 97-101	50.4	709
486	Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. <i>Cell</i> , <b>2009</b> , 138, 245-56	56.2	691
485	The Landscape of Circular RNA in Cancer. <i>Cell</i> , <b>2019</b> , 176, 869-881.e13	56.2	672
484	Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. <i>Nature</i> , <b>2007</b> , 448, 595-9	50.4	654
483	Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. <i>Nature</i> , <b>2014</b> , 510, 278-82	50.4	650
482	An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. <i>Cancer Cell</i> , <b>2010</b> , 17, 443-54	24.3	640
481	CD8 T cells regulate tumour ferroptosis during cancer immunotherapy. <i>Nature</i> , <b>2019</b> , 569, 270-274	50.4	632
480	Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. <i>Cancer Cell</i> , <b>2005</b> , 8, 393-406	24.3	625
479	FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. <i>Journal of Biological Chemistry</i> , <b>1996</b> , 271, 4961-5	5.4	598
478	Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. <i>Science</i> , <b>1996</b> , 274, 990-2	33.3	577

477	Recurrent gene fusions in prostate cancer. <i>Nature Reviews Cancer</i> , <b>2008</b> , 8, 497-511	31.3	554
476	Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. <i>Cancer Discovery</i> , <b>2011</b> , 1, 487-95	24.4	550
475	A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. <i>Molecular Cell</i> , <b>2007</b> , 27, 380-92	17.6	526
474	Role of the TMPRSS2-ERG gene fusion in prostate cancer. <i>Neoplasia</i> , <b>2008</b> , 10, 177-88	6.4	522
473	Autoantibody signatures in prostate cancer. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 1224-35	59.2	521
472	The long noncoding RNA SCHLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. <i>Nature Genetics</i> , <b>2013</b> , 45, 1392-8	36.3	515
471	Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. <i>Nature Genetics</i> , <b>2013</b> , 45, 180-5	36.3	514
470	The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation. <i>Genes and Development</i> , <b>2010</b> , 24, 1106-18	12.6	512
469	Identification of targetable FGFR gene fusions in diverse cancers. <i>Cancer Discovery</i> , <b>2013</b> , 3, 636-47	24.4	511
468	alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. <i>JAMA - Journal of the American Medical Association</i> , <b>2002</b> , 287, 1662-70	27.4	489
467	Molecular ordering of the cell death pathway. Bcl-2 and Bcl-xL function upstream of the CED-3-like apoptotic proteases. <i>Journal of Biological Chemistry</i> , <b>1996</b> , 271, 4573-6	5.4	471
466	Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. <i>Cancer Research</i> , <b>2002</b> , 62, 4427-33	10.1	460
465	Personalized oncology through integrative high-throughput sequencing: a pilot study. <i>Science Translational Medicine</i> , <b>2011</b> , 3, 111ra121	17.5	452
464	Integrative clinical genomics of metastatic cancer. <i>Nature</i> , <b>2017</b> , 548, 297-303	50.4	440
463	TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. <i>Cancer Research</i> , <b>2006</b> , 66, 8337-41	10.1	419
462	The Role of Non-coding RNAs in Oncology. <i>Cell</i> , <b>2019</b> , 179, 1033-1055	56.2	413
461	TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. <i>Cancer Research</i> , <b>2006</b> , 66, 3396-400	10.1	387
460	Genomic correlates of clinical outcome in advanced prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 11428-11436	11.5	383

459	Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. <i>Nature Medicine</i> , <b>2010</b> , 16, 793-8	50.5	382
458	The long tail of oncogenic drivers in prostate cancer. <i>Nature Genetics</i> , <b>2018</b> , 50, 645-651	36.3	380
457	Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. <i>Journal of Cellular Biochemistry</i> , <b>2003</b> , 89, 462-73	4.7	370
456	TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. <i>American Journal of Surgical Pathology</i> , <b>2007</b> , 31, 882-8	6.7	351
455	New class of microRNA targets containing simultaneous 5PUTR and 3PUTR interaction sites. <i>Genome Research</i> , <b>2009</b> , 19, 1175-83	9.7	346
454	Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. <i>Cancer Cell</i> , <b>2011</b> , 19, 664-78	24.3	342
453	Probabilistic model of the human protein-protein interaction network. <i>Nature Biotechnology</i> , <b>2005</b> , 23, 951-9	44.5	338
452	The cell-death machine. <i>Current Biology</i> , <b>1996</b> , 6, 555-62	6.3	334
451	A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. <i>Cancer Research</i> , <b>2008</b> , 68, 645-9	10.1	330
450	Beyond PSA: the next generation of prostate cancer biomarkers. <i>Science Translational Medicine</i> , <b>2012</b> , 4, 127rv3	17.5	313
449	Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). <i>Cancer Research</i> , <b>2005</b> , 65, 3328-35	10.1	313
448	Induced chromosomal proximity and gene fusions in prostate cancer. <i>Science</i> , <b>2009</b> , 326, 1230	33.3	299
447	The bright side of dark matter: lncRNAs in cancer. <i>Journal of Clinical Investigation</i> , <b>2016</b> , 126, 2775-82	15.9	296
446	Antibody-based detection of ERG rearrangement-positive prostate cancer. <i>Neoplasia</i> , <b>2010</b> , 12, 590-8	6.4	281
445	Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. <i>Science Translational Medicine</i> , <b>2011</b> , 3, 94ra72	17.5	281
444	JAGGED1 expression is associated with prostate cancer metastasis and recurrence. <i>Cancer Research</i> , <b>2004</b> , 64, 6854-7	10.1	280
443	ETS gene fusions in prostate cancer: from discovery to daily clinical practice. <i>European Urology</i> , <b>2009</b> , 56, 275-86	10.2	279
442	Chimeric transcript discovery by paired-end transcriptome sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 12353-8	11.5	275

441	A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. <i>Cancer Research</i> , <b>2007</b> , 67, 10657-63	10.1	270
440	Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. <i>Nature Medicine</i> , <b>2011</b> , 17, 1646-51	50.5	262
439	Dual roles of PARP-1 promote cancer growth and progression. <i>Cancer Discovery</i> , <b>2012</b> , 2, 1134-49	24.4	260
438	Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 314, 913-25	27.4	257
437	Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. <i>Cell</i> , <b>2018</b> , 173, 1770-1782.e14	56.2	256
436	The role of SPINK1 in ETS rearrangement-negative prostate cancers. <i>Cancer Cell</i> , <b>2008</b> , 13, 519-28	24.3	254
435	Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11. <i>Cancer Discovery</i> , <b>2019</b> , 9, 1673-1685	24.4	252
434	Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 805-815	15.9	252
433	Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. <i>Journal of the National Cancer Institute</i> , <b>2008</b> , 100, 815-25	9.7	251
432	Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. <i>Modern Pathology</i> , <b>2007</b> , 20, 538-44	9.8	250
431	Ultraviolet radiation-induced apoptosis is mediated by activation of CD-95 (Fas/APO-1). <i>Journal of Biological Chemistry</i> , <b>1997</b> , 272, 25783-6	5.4	246
430	Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. <i>American Journal of Surgical Pathology</i> , <b>2002</b> , 26, 926-31	6.7	236
429	ICE-LAP3, a novel mammalian homologue of the <i>Caenorhabditis elegans</i> cell death protein Ced-3 is activated during Fas- and tumor necrosis factor-induced apoptosis. <i>Journal of Biological Chemistry</i> , <b>1996</b> , 271, 1621-5	5.4	235
428	Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. <i>Nature Immunology</i> , <b>2016</b> , 17, 95-103	19.1	234
427	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. <i>Cell</i> , <b>2018</b> , 174, 758-769.e9	56.2	234
426	Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. <i>Cancer Discovery</i> , <b>2017</b> , 7, 1006-1017	24.4	232
425	Common gene rearrangements in prostate cancer. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 3659-68	2.2	231
424	Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. <i>European Urology</i> , <b>2016</b> , 70, 45-53	10.2	228

4 <sup>23</sup>	ICE-LAP6, a novel member of the ICE/Ced-3 gene family, is activated by the cytotoxic T cell protease granzyme B. <i>Journal of Biological Chemistry</i> , <b>1996</b> , 271, 16720-4	5.4	225
4 <sup>22</sup>	Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. <i>Cancer Research</i> , <b>2005</b> , 65, 11259-64	10.1	221
4 <sup>21</sup>	Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. <i>Cancer Research</i> , <b>2008</b> , 68, 3584-90	10.1	220
4 <sup>20</sup>	Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. <i>Journal of the National Cancer Institute</i> , <b>2003</b> , 95, 661-8	9.7	220
4 <sup>19</sup>	A role for FADD in T cell activation and development. <i>Immunity</i> , <b>1998</b> , 8, 439-49	32.3	218
4 <sup>18</sup>	Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. <i>Cancer Research</i> , <b>2008</b> , 68, 73-80	10.1	212
4 <sup>17</sup>	PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. <i>Cancer Research</i> , <b>2014</b> , 74, 1651-60	10.1	204
4 <sup>16</sup>	PARP-1 inhibition as a targeted strategy to treat Ewing sarcoma. <i>Cancer Research</i> , <b>2012</b> , 72, 1608-13	10.1	203
4 <sup>15</sup>	Expressed pseudogenes in the transcriptional landscape of human cancers. <i>Cell</i> , <b>2012</b> , 149, 1622-34	56.2	203
4 <sup>14</sup>	EML4-ALK fusion lung cancer: a rare acquired event. <i>Neoplasia</i> , <b>2008</b> , 10, 298-302	6.4	201
4 <sup>13</sup>	The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma. <i>Cancer Research</i> , <b>2015</b> , 75, 3720-3727	10.1	196
4 <sup>12</sup>	RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SCHLAP1. <i>Lancet Oncology</i> , <b>2014</b> , 15, 1469-1480	21.7	192
4 <sup>11</sup>	Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. <i>Modern Pathology</i> , <b>2009</b> , 22, 1083-93	9.8	190
4 <sup>10</sup>	Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. <i>Cancer Research</i> , <b>2006</b> , 66, 3903-11	10.1	190
4 <sup>09</sup>	The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc. <i>Neoplasia</i> , <b>2014</b> , 16, 900-8	6.4	187
4 <sup>08</sup>	Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. <i>Cancer Cell</i> , <b>2007</b> , 12, 419-31	24.3	185
4 <sup>07</sup>	A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. <i>Cancer Research</i> , <b>2005</b> , 65, 1213-22	10.1	182
4 <sup>06</sup>	Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 4706-11	12.9	181

405	Long noncoding RNAs in cancer: from function to translation. <i>Trends in Cancer</i> , <b>2015</b> , 1, 93-109	12.5	179
404	Coordinated regulation of polycomb group complexes through microRNAs in cancer. <i>Cancer Cell</i> , <b>2011</b> , 20, 187-99	24.3	176
403	Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. <i>Cancer Research</i> , <b>2007</b> , 67, 7991-5	10.1	176
402	Role of CED-4 in the activation of CED-3. <i>Nature</i> , <b>1997</b> , 388, 728-9	50.4	174
401	Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. <i>Neoplasia</i> , <b>2006</b> , 8, 885-8	6.4	174
400	Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. <i>Cell</i> , <b>2019</b> , 179, 964-983.e31	31.1	173
399	Nod1 acts as an intracellular receptor to stimulate chemokine production and neutrophil recruitment in vivo. <i>Journal of Experimental Medicine</i> , <b>2006</b> , 203, 203-13	16.6	173
398	Molecular signatures of sepsis: multiorgan gene expression profiles of systemic inflammation. <i>American Journal of Pathology</i> , <b>2001</b> , 159, 1199-209	5.8	173
397	The Potential of MicroRNAs as Prostate Cancer Biomarkers. <i>European Urology</i> , <b>2016</b> , 70, 312-22	10.2	169
396	Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. <i>Prostate</i> , <b>2006</b> , 66, 248-56	4.2	167
395	Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. <i>Cancer Research</i> , <b>2009</b> , 69, 4434-42	10.1	162
394	FIZZ1 stimulation of myofibroblast differentiation. <i>American Journal of Pathology</i> , <b>2004</b> , 164, 1315-26	5.8	161
393	Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2013</b> , 31, 566-71	2.8	160
392	Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. <i>Human Molecular Genetics</i> , <b>2004</b> , 13, 1303-13	5.6	158
391	The apoptosome: heart and soul of the cell death machine. <i>Neoplasia</i> , <b>1999</b> , 1, 5-15	6.4	157
390	Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. <i>Neoplasia</i> , <b>2015</b> , 17, 385-99	6.4	156
389	Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. <i>Genome Research</i> , <b>2011</b> , 21, 56-67	9.7	156
388	Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA. <i>Cell</i> , <b>2017</b> , 171, 1559-1572.e30	30.2	153



387	The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. <i>Nature Communications</i> , <b>2016</b> , 7, 12791	17.4	152
386	Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2007</b> , 104, 19488-93	11.5	152
385	Mining for regulatory programs in the cancer transcriptome. <i>Nature Genetics</i> , <b>2005</b> , 37, 579-83	36.3	150
384	Dysregulation of the annexin family protein family is associated with prostate cancer progression. <i>American Journal of Pathology</i> , <b>2003</b> , 162, 255-61	5.8	149
383	Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. <i>Genome Research</i> , <b>2011</b> , 21, 1028-41	9.7	144
382	Comparative analysis of circulating tumor DNA stability in KEDTA, Streck, and CellSave blood collection tubes. <i>Clinical Biochemistry</i> , <b>2016</b> , 49, 1354-1360	3.5	141
381	Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma. <i>Cell</i> , <b>2020</b> , 182, 200-225.e35	56.2	139
380	Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. <i>JAMA Oncology</i> , <b>2017</b> , 3, 1663-1672	13.4	138
379	Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. <i>Cancer Research</i> , <b>2004</b> , 64, 3814-22	10.1	136
378	Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. <i>Cancer Research</i> , <b>2003</b> , 63, 132-9	10.1	136
377	Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements. <i>American Journal of Pathology</i> , <b>2004</b> , 164, 831-40	5.8	135
376	Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. <i>Genome Research</i> , <b>2011</b> , 21, 47-55	9.7	134
375	The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells. <i>Journal of Biological Chemistry</i> , <b>2003</b> , 278, 1372-9	5.4	134
374	C5a-induced gene expression in human umbilical vein endothelial cells. <i>American Journal of Pathology</i> , <b>2004</b> , 164, 849-59	5.8	134
373	ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 993-9	12.9	129
372	Cancer transcriptome profiling at the juncture of clinical translation. <i>Nature Reviews Genetics</i> , <b>2018</b> , 19, 93-109	30.1	128
371	A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. <i>Cancer Research</i> , <b>2008</b> , 68, 7629-37	10.1	127
370	Targeting the MLL complex in castration-resistant prostate cancer. <i>Nature Medicine</i> , <b>2015</b> , 21, 344-52	50.5	126

369	Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimens. <i>American Journal of Pathology</i> , <b>2002</b> , 161, 1743-8	5.8	124
368	Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. <i>PLoS ONE</i> , <b>2013</b> , 8, e69239	3.7	124
367	Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression. <i>Nature Genetics</i> , <b>2018</b> , 50, 814-824	36.3	124
366	BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer. <i>Molecular Cancer Research</i> , <b>2016</b> , 14, 324-31	6.6	120
365	Therapeutic targeting of SPINK1-positive prostate cancer. <i>Science Translational Medicine</i> , <b>2011</b> , 3, 72ra17.5	17.5	120
364	The lethal phenotype of cancer: the molecular basis of death due to malignancy. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2007</b> , 57, 225-41	220.7	120
363	Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. <i>Neoplasia</i> , <b>2007</b> , 9, 443-54	6.4	118
362	Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 991-999	2.2	117
361	Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. <i>Nature Medicine</i> , <b>2021</b> , 27, 152-164	50.5	117
360	SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. <i>Cancer Cell</i> , <b>2017</b> , 31, 436-451	24.3	116
359	Targeting of microRNA-142-3p in dendritic cells regulates endotoxin-induced mortality. <i>Blood</i> , <b>2011</b> , 117, 6172-83	2.2	116
358	The role of metastasis-associated protein 1 in prostate cancer progression. <i>Cancer Research</i> , <b>2004</b> , 64, 825-9	10.1	116
357	Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. <i>Journal of the National Cancer Institute</i> , <b>2004</b> , 96, 834-43	9.7	113
356	Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. <i>Oncotarget</i> , <b>2012</b> , 3, 1011-25	3.3	113
355	The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencing. <i>Genome Research</i> , <b>2015</b> , 25, 1372-81	9.7	112
354	The role of sarcosine metabolism in prostate cancer progression. <i>Neoplasia</i> , <b>2013</b> , 15, 491-501	6.4	111
353	AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 10284-9	11.5	111
352	Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. <i>Molecular Cell</i> , <b>2013</b> , 49, 80-93	17.6	110

351	Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	110
350	The landscape of antisense gene expression in human cancers. <i>Genome Research</i> , <b>2015</b> , 25, 1068-79	9.7	110
349	Melanoma proliferation and chemoresistance controlled by the DEK oncogene. <i>Cancer Research</i> , <b>2009</b> , 69, 6405-13	10.1	110
348	Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 366ra161	17.5	109
347	Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 1983-93	12.9	108
346	Translating cancer genomes and transcriptomes for precision oncology. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2016</b> , 66, 75-88	220.7	108
345	Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. <i>American Journal of Human Genetics</i> , <b>2016</b> , 98, 1051-1066	11	107
344	Triggers for genomic rearrangements: insights into genomic, cellular and environmental influences. <i>Nature Reviews Genetics</i> , <b>2010</b> , 11, 819-29	30.1	106
343	alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation. <i>American Journal of Pathology</i> , <b>2002</b> , 161, 841-8	5.8	105
342	Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. <i>Neoplasia</i> , <b>2007</b> , 9, 200-6	6.4	104
341	The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer. <i>Molecular Cancer Research</i> , <b>2014</b> , 12, 1081-7	6.6	103
340	CXCL5 promotes prostate cancer progression. <i>Neoplasia</i> , <b>2008</b> , 10, 244-54	6.4	103
339	Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues. <i>Cancer Research</i> , <b>2006</b> , 66, 4095-9	10.1	103
338	Landscape of gene fusions in epithelial cancers: seq and ye shall find. <i>Genome Medicine</i> , <b>2015</b> , 7, 129	14.4	102
337	Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes. <i>Nature Communications</i> , <b>2014</b> , 5, 5893	17.4	100
336	Nuclear versus cytoplasmic localization of filamin A in prostate cancer: immunohistochemical correlation with metastases. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 788-96	12.9	100
335	The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of	5	99
334	Overexpression of the Long Non-coding RNA-SChLAP1 Independently Predicts Lethal Prostate Cancer. <i>European Urology</i> , <b>2016</b> , 70, 549-552	10.2	98

333	Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. <i>Molecular Cancer Therapeutics</i> , <b>2006</b> , 5, 3096-104	6.1	98
332	Cancer SLC43A2 alters T cell methionine metabolism and histone methylation. <i>Nature</i> , <b>2020</b> , 585, 277-283	50.4	98
331	Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. <i>Cancer Research</i> , <b>2012</b> , 72, 616-25	10.1	97
330	Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer. <i>Nature</i> , <b>2019</b> , 571, 413-418	50.4	96
329	Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer. <i>Molecular and Cellular Proteomics</i> , <b>2010</b> , 9, 298-312	7.6	96
328	Integrative analysis of genomic aberrations associated with prostate cancer progression. <i>Cancer Research</i> , <b>2007</b> , 67, 8229-39	10.1	96
327	Current affairs in quantitative targeted proteomics: multiple reaction monitoring-mass spectrometry. <i>Briefings in Functional Genomics &amp; Proteomics</i> , <b>2009</b> , 8, 145-57		95
326	Cytotoxic T-cell-derived granzyme B activates the apoptotic protease ICE-LAP3. <i>Current Biology</i> , <b>1996</b> , 6, 897-9	6.3	93
325	The central role of EED in the orchestration of polycomb group complexes. <i>Nature Communications</i> , <b>2014</b> , 5, 3127	17.4	91
324	A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. <i>Nature Genetics</i> , <b>2018</b> , 50, 979-989	36.3	90
323	KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. <i>Journal of Clinical Investigation</i> , <b>2008</b> , 118, 2711-21	15.9	89
322	Magic angle spinning NMR-based metabolic profiling of head and neck squamous cell carcinoma tissues. <i>Journal of Proteome Research</i> , <b>2011</b> , 10, 5232-41	5.6	87
321	Portrait of an executioner: the molecular mechanism of FAS/APO-1-induced apoptosis. <i>Seminars in Immunology</i> , <b>1997</b> , 9, 69-76	10.7	87
320	The lncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer. <i>Oncotarget</i> , <b>2014</b> , 5, 1434-8	3.3	84
319	Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 4441-4453	15.9	84
318	Characterization of KRAS rearrangements in metastatic prostate cancer. <i>Cancer Discovery</i> , <b>2011</b> , 1, 35-43	24.4	83
317	A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. <i>Urology</i> , <b>2002</b> , 60, 760-5	1.6	83
316	On the detection and refinement of transcription factor binding sites using ChIP-Seq data. <i>Nucleic Acids Research</i> , <b>2010</b> , 38, 2154-67	20.1	82

315	TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer. <i>Nature Communications</i> , <b>2014</b> , 5, 4527	17.4	81
314	Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer. <i>American Journal of Pathology</i> , <b>2018</b> , 188, 1478-1485	5.8	79
313	The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells. <i>Neoplasia</i> , <b>2005</b> , 7, 1011-0.4	0.4	79
312	Classification and selection of biomarkers in genomic data using LASSO. <i>Journal of Biomedicine and Biotechnology</i> , <b>2005</b> , 2005, 147-54		79
311	Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2012</b> , 136, 935-46	5	78
310	Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 691-700	12.9	78
309	SUN-003 Targeting Androgen Receptor-CXCR7-MARK Signaling Axis in CRPC. <i>Journal of the Endocrine Society</i> , <b>2019</b> , 3,	0.4	78
308	DIPG-59. UPREGULATION OF PRENATAL PONTINE ID1 SIGNALING IN DIPG. <i>Neuro-Oncology</i> , <b>2020</b> , 22, iii298-iii299	1	78
307	Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC). <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 3149-3162	12.9	77
306	Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. <i>Modern Pathology</i> , <b>2009</b> , 22, 1176-85	9.8	77
305	The inhibition of pro-apoptotic ICE-like proteases enhances HIV replication. <i>Nature Medicine</i> , <b>1997</b> , 3, 333-7	50.5	76
304	Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma. <i>Cancer Research</i> , <b>2007</b> , 67, 3461-7	10.1	76
303	Molecular cross-talk between the TRAIL and interferon signaling pathways. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 575-85	5.4	75
302	ETS gene aberrations in atypical cribriform lesions of the prostate: Implications for the distinction between intraductal carcinoma of the prostate and cribriform high-grade prostatic intraepithelial neoplasia. <i>American Journal of Surgical Pathology</i> , <b>2010</b> , 34, 478-85	6.7	74
301	Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer. <i>Neoplasia</i> , <b>2008</b> , 10, 1285-94	6.4	74
300	Targeting transcriptional regulation of SARS-CoV-2 entry factors and. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> ,	11.5	74
299	Defining aggressive prostate cancer using a 12-gene model. <i>Neoplasia</i> , <b>2006</b> , 8, 59-68	6.4	73
298	ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease. <i>Neoplasia</i> , <b>2006</b> , 8, 319-29	6.4	73

297	Integration of high-resolution array comparative genomic hybridization analysis of chromosome 16q with expression array data refines common regions of loss at 16q23-qter and identifies underlying candidate tumor suppressor genes in prostate cancer. <i>Oncogene</i> , <b>2004</b> , 23, 3487-94	9.2	73
296	TACO produces robust multisample transcriptome assemblies from RNA-seq. <i>Nature Methods</i> , <b>2017</b> , 14, 68-70	21.6	72
295	Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. <i>Science Translational Medicine</i> , <b>2014</b> , 6, 252ra122	17.5	71
294	A novel RNA in situ hybridization assay for the long noncoding RNA SCHLAP1 predicts poor clinical outcome after radical prostatectomy in clinically localized prostate cancer. <i>Neoplasia</i> , <b>2014</b> , 16, 1121-7	6.4	71
293	The DNA methylation landscape of advanced prostate cancer. <i>Nature Genetics</i> , <b>2020</b> , 52, 778-789	36.3	71
292	Advancing precision medicine for prostate cancer through genomics. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1866-73	2.2	70
291	The miR-124-prolyl hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression. <i>Oncotarget</i> , <b>2014</b> , 5, 6654-69	3.3	70
290	Estrogen receptor mutations and their role in breast cancer progression. <i>Breast Cancer Research</i> , <b>2014</b> , 16, 494	8.3	69
289	Delineating metabolic signatures of head and neck squamous cell carcinoma: phospholipase A2, a potential therapeutic target. <i>International Journal of Biochemistry and Cell Biology</i> , <b>2012</b> , 44, 1852-61	5.6	69
288	Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence. <i>Journal of Urology</i> , <b>2016</b> , 196, 405-11	2.5	67
287	Precision oncology in the age of integrative genomics. <i>Nature Biotechnology</i> , <b>2018</b> , 36, 46-60	44.5	65
286	Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. <i>Neoplasia</i> , <b>2011</b> , 13, 1019-25	6.4	65
285	The DEK oncoprotein is a Su(var) that is essential to heterochromatin integrity. <i>Genes and Development</i> , <b>2011</b> , 25, 673-8	12.6	65
284	RhoC induces differential expression of genes involved in invasion and metastasis in MCF10A breast cells. <i>Breast Cancer Research and Treatment</i> , <b>2004</b> , 84, 3-12	4.4	65
283	Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden. <i>American Journal of Clinical Pathology</i> , <b>2012</b> , 138, 685-96	1.9	64
282	The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 6447-52	12.9	64
281	Germline Findings in Tumor-Only Sequencing: Points to Consider for Clinicians and Laboratories. <i>Journal of the National Cancer Institute</i> , <b>2016</b> , 108,	9.7	63
280	An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. <i>Nature Biotechnology</i> , <b>2009</b> , 27, 1005-11	44.5	63

279	Statistical issues and methods for meta-analysis of microarray data: a case study in prostate cancer. <i>Functional and Integrative Genomics</i> , <b>2003</b> , 3, 180-8	3.8	63
278	Coactivator SRC-2-dependent metabolic reprogramming mediates prostate cancer survival and metastasis. <i>Journal of Clinical Investigation</i> , <b>2015</b> , 125, 1174-88	15.9	63
277	A dual role for receptor-interacting protein kinase 2 (RIP2) kinase activity in nucleotide-binding oligomerization domain 2 (NOD2)-dependent autophagy. <i>Journal of Biological Chemistry</i> , <b>2012</b> , 287, 25585-76	5.4	62
276	Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer. <i>American Journal of Pathology</i> , <b>2004</b> , 164, 787-93	5.8	62
275	Oncogenic gene fusions in epithelial carcinomas. <i>Current Opinion in Genetics and Development</i> , <b>2009</b> , 19, 82-91	4.9	60
274	Characterization of bone metastases from rapid autopsies of prostate cancer patients. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 3924-32	12.9	60
273	Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms. <i>Cancer Research</i> , <b>2018</b> , 78, 1110-1122	10.1	60
272	Dynamic Recruitment of Single RNAs to Processing Bodies Depends on RNA Functionality. <i>Molecular Cell</i> , <b>2019</b> , 74, 521-533.e6	17.6	58
271	KRAS protein stability is regulated through SMURF2: UBC5 complex-mediated TrCP1 degradation. <i>Neoplasia</i> , <b>2014</b> , 16, 115-28	6.4	58
270	RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease. <i>Neoplasia</i> , <b>2009</b> , 11, 956-63	6.4	58
269	Molecular markers of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2006</b> , 24, 538-51	2.8	58
268	Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment. <i>Neoplasia</i> , <b>2020</b> , 22, 111-119	6.4	58
267	Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. <i>Cancer Cell</i> , <b>2017</b> , 31, 532-548.e7	24.3	57
266	Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1. <i>American Journal of Pathology</i> , <b>2008</b> , 172, 893-904	5.8	56
265	Feature selection and molecular classification of cancer using genetic programming. <i>Neoplasia</i> , <b>2007</b> , 9, 292-303	6.4	56
264	Bioinformatics approaches in the study of cancer. <i>Current Molecular Medicine</i> , <b>2007</b> , 7, 133-41	2.5	56
263	Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells. <i>Blood</i> , <b>2012</b> , 119, 1274-82	2.2	54
262	Galanin modulates the neural niche to favour perineural invasion in head and neck cancer. <i>Nature Communications</i> , <b>2015</b> , 6, 6885	17.4	53

261	Analysis of the tau-associated proteome reveals that exchange of Hsp70 for Hsp90 is involved in tau degradation. <i>ACS Chemical Biology</i> , <b>2012</b> , 7, 1677-86	4.9	53
260	Inflammation-Induced Oxidative Stress Mediates Gene Fusion Formation in Prostate Cancer. <i>Cell Reports</i> , <b>2016</b> , 17, 2620-2631	10.6	52
259	Precision medicine in pediatric oncology: Lessons learned and next steps. <i>Pediatric Blood and Cancer</i> , <b>2017</b> , 64, e26288	3	51
258	HIV infection reveals widespread expansion of novel centromeric human endogenous retroviruses. <i>Genome Research</i> , <b>2013</b> , 23, 1505-13	9.7	51
257	Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures. <i>Journal of Proteome Research</i> , <b>2009</b> , 8, 3044-54	5.6	51
256	Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 696-707	12.9	51
255	Gene fusions associated with recurrent amplicons represent a class of passenger aberrations in breast cancer. <i>Neoplasia</i> , <b>2012</b> , 14, 702-8	6.4	50
254	Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. <i>Cancer Cell</i> , <b>2021</b> , 39, 361-379.e16	24.3	50
253	Role and regulation of coordinately expressed de novo purine biosynthetic enzymes PPAT and PAICS in lung cancer. <i>Oncotarget</i> , <b>2015</b> , 6, 23445-61	3.3	49
252	Role of transcriptional corepressor CtBP1 in prostate cancer progression. <i>Neoplasia</i> , <b>2012</b> , 14, 905-14	6.4	49
251	Bioinformatics strategies for translating genome-wide expression analyses into clinically useful cancer markers. <i>Annals of the New York Academy of Sciences</i> , <b>2004</b> , 1020, 32-40	6.5	49
250	Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency. <i>European Urology</i> , <b>2019</b> , 75, 184-192	10.2	49
249	The CARMA3-Bcl10-MALT1 Signalingosome Drives NF $\kappa$ B Activation and Promotes Aggressiveness in Angiotensin II Receptor-Positive Breast Cancer. <i>Cancer Research</i> , <b>2018</b> , 78, 1225-1240	10.1	48
248	From bytes to bedside: data integration and computational biology for translational cancer research. <i>PLoS Computational Biology</i> , <b>2007</b> , 3, e12	5	48
247	Biallelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney. <i>Cancer Discovery</i> , <b>2016</b> , 6, 1258-1266	24.4	48
246	Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer. <i>Cancer Research</i> , <b>2005</b> , 65, 4126-33	10.1	47
245	Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays. <i>Modern Pathology</i> , <b>2018</b> , 31, 179-197	9.8	46
244	ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. <i>Neoplasia</i> , <b>2010</b> , 12, 1031-40	6.4	46



243	The unfolded protein response modulates toxicity of the expanded glutamine androgen receptor. <i>Journal of Biological Chemistry</i> , <b>2005</b> , 280, 21264-71	5.4	46
242	Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer. <i>Journal of Proteome Research</i> , <b>2014</b> , 13, 1088-100	5.6	45
241	Humoral response profiling reveals pathways to prostate cancer progression. <i>Molecular and Cellular Proteomics</i> , <b>2008</b> , 7, 600-11	7.6	45
240	Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 2712-2726	15.9	45
239	Molecular pathways: targeting ETS gene fusions in cancer. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 4442-8	12.9	44
238	De novo dominant ASXL3 mutations alter H2A deubiquitination and transcription in Bainbridge-Ropers syndrome. <i>Human Molecular Genetics</i> , <b>2016</b> , 25, 597-608	5.6	43
237	Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells. <i>Cancer Research</i> , <b>2010</b> , 70, 5994-6003	10.1	43
236	Cancer immunomics: using autoantibody signatures in the early detection of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2006</b> , 24, 237-42	2.8	43
235	Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer. <i>Cancer Research</i> , <b>2019</b> , 79, 2580-2592	10.1	42
234	HR-MAS NMR tissue metabolomic signatures cross-validated by mass spectrometry distinguish bladder cancer from benign disease. <i>Journal of Proteome Research</i> , <b>2013</b> , 12, 3519-28	5.6	42
233	Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma. <i>Modern Pathology</i> , <b>2013</b> , 26, 835-48	9.8	42
232	Exploring clinical associations using PomicsPbased enrichment analyses. <i>PLoS ONE</i> , <b>2009</b> , 4, e5203	3.7	42
231	Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 6686-91	11.5	42
230	A comparison of single molecule and amplification based sequencing of cancer transcriptomes. <i>PLoS ONE</i> , <b>2011</b> , 6, e17305	3.7	42
229	Non-coding RNA LINC00857 is predictive of poor patient survival and promotes tumor progression via cell cycle regulation in lung cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 11487-99	3.3	42
228	The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. <i>European Urology</i> , <b>2017</b> , 71, 237-246	10.2	41
227	The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications. <i>Advances in Anatomic Pathology</i> , <b>2009</b> , 16, 145-53	5.1	41
226	AZGP1 autoantibody predicts survival and histone deacetylase inhibitors increase expression in lung adenocarcinoma. <i>Journal of Thoracic Oncology</i> , <b>2008</b> , 3, 1236-44	8.9	41

225	Selection and cloning of poly(rC)-binding protein 2 and Raf kinase inhibitor protein RNA activators of 2P5Poligoadenylate synthetase from prostate cancer cells. <i>Nucleic Acids Research</i> , <b>2006</b> , 34, 6684-95	20.1	41
224	Transcriptomic heterogeneity in multifocal prostate cancer. <i>JCI Insight</i> , <b>2018</b> , 3,	9.9	41
223	Somatic Bi-allelic Loss of TSC Genes in Eosinophilic Solid and Cystic Renal Cell Carcinoma. <i>European Urology</i> , <b>2018</b> , 74, 483-486	10.2	41
222	TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers. <i>Cancer Research</i> , <b>2011</b> , 71, 5387-92	10.1	40
221	Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition. <i>Neoplasia</i> , <b>2013</b> , 15, 1207-17	6.4	39
220	Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors. <i>Neoplasia</i> , <b>2004</b> , 6, 503-12	6.4	39
219	Proteomic interrogation of androgen action in prostate cancer cells reveals roles of aminoacyl tRNA synthetases. <i>PLoS ONE</i> , <b>2009</b> , 4, e7075	3.7	39
218	Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer. <i>European Urology</i> , <b>2020</b> , 77, 333-341	10.2	39
217	Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,	11.5	39
216	CCL2 induces prostate cancer transendothelial cell migration via activation of the small GTPase Rac. <i>Journal of Cellular Biochemistry</i> , <b>2008</b> , 104, 1587-97	4.7	38
215	Whole transcriptome amplification for gene expression profiling and development of molecular archives. <i>Neoplasia</i> , <b>2006</b> , 8, 153-62	6.4	38
214	Development of an internally controlled antibody microarray. <i>Molecular and Cellular Proteomics</i> , <b>2005</b> , 4, 1664-72	7.6	37
213	Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer. <i>Neoplasia</i> , <b>2016</b> , 18, 489-99	6.4	37
212	HRAS mutations are frequent in inverted urothelial neoplasms. <i>Human Pathology</i> , <b>2014</b> , 45, 1957-65	3.7	36
211	Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. <i>Oncotarget</i> , <b>2017</b> , 8, 89848-89866	3.3	36
210	Molecular and immunohistochemical characterization reveals novel BRAF mutations in metanephric adenoma. <i>American Journal of Surgical Pathology</i> , <b>2015</b> , 39, 549-57	6.7	35
209	MechRNA: prediction of lncRNA mechanisms from RNA-RNA and RNA-protein interactions. <i>Bioinformatics</i> , <b>2018</b> , 34, 3101-3110	7.2	35
208	HOXB13 G84E-related familial prostate cancers: a clinical, histologic, and molecular survey. <i>American Journal of Surgical Pathology</i> , <b>2014</b> , 38, 615-26	6.7	35

207	Noncoding RNAs and cancer. <i>Cell</i> , <b>2013</b> , 153, 9-10	56.2	35
206	Recurrent reciprocal RNA chimera involving YPEL5 and PPP1CB in chronic lymphocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 3035-40	11.5	35
205	Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 6721-6730	12.9	35
204	A clonal expression biomarker associates with lung cancer mortality. <i>Nature Medicine</i> , <b>2019</b> , 25, 1540-1548	18.5	34
203	Circumscribed/non-diffuse histology confers a better prognosis in H3K27M-mutant gliomas. <i>Acta Neuropathologica</i> , <b>2018</b> , 135, 299-301	14.3	34
202	Primary urethral clear-cell adenocarcinoma: comprehensive analysis by surgical pathology, cytopathology, and next-generation sequencing. <i>American Journal of Pathology</i> , <b>2014</b> , 184, 584-91	5.8	34
201	SLC45A3-ELK4 chimera in prostate cancer: spotlight on cis-splicing. <i>Cancer Discovery</i> , <b>2012</b> , 2, 582-5	24.4	34
200	Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2014</b> , 465, 623-8	5.1	33
199	Outlier kinase expression by RNA sequencing as targets for precision therapy. <i>Cancer Discovery</i> , <b>2013</b> , 3, 280-93	24.4	33
198	Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition. <i>International Journal of Cancer</i> , <b>2006</b> , 118, 1041-50	7.5	33
197	miR-34a directly targets tRNA precursors and affects cellular proliferation, cell cycle, and apoptosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, 7392-7397	11.5	33
196	Polycomb group proteins EZH2 and EED directly regulate androgen receptor in advanced prostate cancer. <i>International Journal of Cancer</i> , <b>2019</b> , 145, 415-426	7.5	32
195	Evaluation of tissue PCA3 expression in prostate cancer by RNA in situ hybridization--a correlative study with urine PCA3 and TMPRSS2-ERG. <i>Modern Pathology</i> , <b>2014</b> , 27, 609-20	9.8	32
194	Development of a multiplex quantitative PCR signature to predict progression in non-muscle-invasive bladder cancer. <i>Cancer Research</i> , <b>2009</b> , 69, 3810-8	10.1	32
193	miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression. <i>Molecular Cancer Research</i> , <b>2018</b> , 16, 1125-1137	6.6	31
192	Expression of PDL1 (B7-H1) Before and After Neoadjuvant Chemotherapy in Urothelial Carcinoma. <i>European Urology Focus</i> , <b>2016</b> , 1, 265-268	5.1	31
191	Clinical tumor sequencing: an incidental casualty of the American College of Medical Genetics and Genomics recommendations for reporting of incidental findings. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2203-5	2.2	31
190	The utility of SDHB and FH immunohistochemistry in patients evaluated for hereditary paraganglioma-pheochromocytoma syndromes. <i>Human Pathology</i> , <b>2018</b> , 71, 47-54	3.7	30

189	Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target. <i>Molecular Cancer Therapeutics</i> , <b>2012</b> , 11, 775-83	6.1	30
188	A transcriptional fingerprint of estrogen in human breast cancer predicts patient survival. <i>Neoplasia</i> , <b>2008</b> , 10, 79-88	6.4	30
187	Integrated Metabolic and Epigenomic Reprogramming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas. <i>Cancer Cell</i> , <b>2020</b> , 38, 334-349.e9	24.3	30
186	Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , <b>2018</b> , 78, 5731-5740	19.1	29
185	"Topological significance" analysis of gene expression and proteomic profiles from prostate cancer cells reveals key mechanisms of androgen response. <i>PLoS ONE</i> , <b>2010</b> , 5, e10936	3.7	29
184	The discovery and application of gene fusions in prostate cancer. <i>BJU International</i> , <b>2008</b> , 102, 276-82	5.6	29
183	Usefulness of a monoclonal ERG/FLI1 antibody for immunohistochemical discrimination of Ewing family tumors. <i>American Journal of Clinical Pathology</i> , <b>2013</b> , 139, 771-9	1.9	28
182	Differential phosphoprotein mapping in cancer cells using protein microarrays produced from 2-D liquid fractionation. <i>Analytical Chemistry</i> , <b>2006</b> , 78, 702-10	7.8	28
181	Bioinformatics approach leads to the discovery of the TMPRSS2:ETS gene fusion in prostate cancer. <i>Laboratory Investigation</i> , <b>2006</b> , 86, 1099-102	5.9	28
180	The death inhibitory molecules CED-9 and CED-4L use a common mechanism to inhibit the CED-3 death protease. <i>Journal of Biological Chemistry</i> , <b>1998</b> , 273, 17708-12	5.4	28
179	TTK inhibition radiosensitizes basal-like breast cancer through impaired homologous recombination. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 958-973	15.9	28
178	Allogeneic T cell responses are regulated by a specific miRNA-mRNA network. <i>Journal of Clinical Investigation</i> , <b>2013</b> , 123, 4739-54	15.9	28
177	KRAS Engages AGO2 to Enhance Cellular Transformation. <i>Cell Reports</i> , <b>2016</b> , 14, 1448-1461	10.6	27
176	Expression and Role of PAICS, a De Novo Purine Biosynthetic Gene in Prostate Cancer. <i>Prostate</i> , <b>2017</b> , 77, 10-21	4.2	27
175	Next-generation RNA Sequencing-based Biomarker Characterization of Chromophobe Renal Cell Carcinoma and Related Oncocytic Neoplasms. <i>European Urology</i> , <b>2020</b> , 78, 63-74	10.2	26
174	-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade. <i>JCO Precision Oncology</i> , <b>2020</b> , 4, 382-392	3.6	26
173	High and selective expression of yeast cytosine deaminase under a carcinoembryonic antigen promoter-enhancer. <i>Cancer Research</i> , <b>2002</b> , 62, 2337-42	10.1	26
172	Comprehensive Molecular Profiling of Olfactory Neuroblastoma Identifies Potentially Targetable Amplifications. <i>Molecular Cancer Research</i> , <b>2017</b> , 15, 1551-1557	6.6	25

171	Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration-resistant prostate cancer. <i>Prostate</i> , <b>2014</b> , 74, 1199-208	4.2	25
170	RNA-Seq accurately identifies cancer biomarker signatures to distinguish tissue of origin. <i>Neoplasia</i> , <b>2014</b> , 16, 918-27	6.4	25
169	Variable reference alignment: an improved peak alignment protocol for NMR spectral data with large intersample variation. <i>Analytical Chemistry</i> , <b>2012</b> , 84, 5372-9	7.8	25
168	Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes. <i>Nature Communications</i> , <b>2021</b> , 12, 935	17.4	25
167	Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. <i>Molecular Cancer Research</i> , <b>2018</b> , 16, 643-654	6.6	24
166	Genomic outlier profile analysis: mixture models, null hypotheses, and nonparametric estimation. <i>Biostatistics</i> , <b>2009</b> , 10, 60-9	3.7	24
165	Ataxia telangiectasia mutated down-regulates phospho-extracellular signal-regulated kinase 1/2 via activation of MKP-1 in response to radiation. <i>Cancer Research</i> , <b>2006</b> , 66, 11554-9	10.1	24
164	VSTM2A Overexpression Is a Sensitive and Specific Biomarker for Mucinous Tubular and Spindle Cell Carcinoma (MTSCC) of the Kidney. <i>American Journal of Surgical Pathology</i> , <b>2018</b> , 42, 1571-1584	6.7	24
163	The role of the histone H3 variant CENPA in prostate cancer. <i>Journal of Biological Chemistry</i> , <b>2020</b> , 295, 8537-8549	5.4	23
162	MicroRNA expression patterns in indeterminate inflammatory bowel disease. <i>Modern Pathology</i> , <b>2013</b> , 26, 148-54	9.8	23
161	Age and Gender Associations of Virus Positivity in Merkel Cell Carcinoma Characterized Using a Novel RNA Hybridization Assay. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 5622-5630	12.9	22
160	Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification. <i>Human Pathology</i> , <b>2014</b> , 45, 2136-43	3.7	22
159	Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 6070-6077	12.9	22
158	Two-pass alignment improves novel splice junction quantification. <i>Bioinformatics</i> , <b>2016</b> , 32, 43-9	7.2	21
157	Papillary renal cell carcinoma revisited: a comprehensive histomorphologic study with outcome correlations. <i>Human Pathology</i> , <b>2014</b> , 45, 1139-46	3.7	21
156	Immunohistochemical staining characteristics of nephrogenic adenoma using the PIN-4 cocktail (p63, AMACR, and CK903) and GATA-3. <i>American Journal of Surgical Pathology</i> , <b>2014</b> , 38, 1664-71	6.7	21
155	Systematic, evidence-based discovery of biomarkers at the NCI. <i>Clinical and Experimental Metastasis</i> , <b>2012</b> , 29, 645-52	4.7	21
154	Applications of genetic programming in cancer research. <i>International Journal of Biochemistry and Cell Biology</i> , <b>2009</b> , 41, 405-13	5.6	21

153	The registry case finding engine: an automated tool to identify cancer cases from unstructured, free-text pathology reports and clinical notes. <i>Journal of the American College of Surgeons</i> , <b>2007</b> , 205, 690-7	4.4	21
152	Immunohistochemical Characterization of Fumarate Hydratase (FH) and Succinate Dehydrogenase (SDH) in Cutaneous Leiomyomas for Detection of Familial Cancer Syndromes. <i>American Journal of Surgical Pathology</i> , <b>2017</b> , 41, 801-809	6.7	20
151	Antibody-independent targeted quantification of TMPRSS2-ERG fusion protein products in prostate cancer. <i>Molecular Oncology</i> , <b>2014</b> , 8, 1169-80	7.9	20
150	Next-generation sequencing identifies the DanforthB short tail mouse mutation as a retrotransposon insertion affecting Ptf1a expression. <i>PLoS Genetics</i> , <b>2013</b> , 9, e1003205	6	20
149	Development of selected reaction monitoring-MS methodology to measure peptide biomarkers in prostate cancer. <i>Proteomics</i> , <b>2010</b> , 10, 3506-14	4.8	20
148	Multivalent Proteins Rapidly and Reversibly Phase-Separate upon Osmotic Cell Volume Change. <i>Molecular Cell</i> , <b>2020</b> , 79, 978-990.e5	17.6	20
147	Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance. <i>Cancer Cell</i> , <b>2021</b> , 39, 480-493.e6	24.3	20
146	Next-generation sequencing in precision oncology: Patient understanding and expectations. <i>Cancer Medicine</i> , <b>2019</b> , 8, 227-237	4.8	20
145	Clinical validation of the Tempus xO assay. <i>Oncotarget</i> , <b>2018</b> , 9, 25826-25832	3.3	20
144	The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 4933-4946	12.9	19
143	Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer. <i>Neoplasia</i> , <b>2016</b> , 18, 1-9	6.4	19
142	Chromosomal aberrations in solid tumors. <i>Progress in Molecular Biology and Translational Science</i> , <b>2010</b> , 95, 55-94	4	19
141	Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors. <i>JAMA Oncology</i> , <b>2021</b> , 7, 525-533	13.4	19
140	Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma. <i>European Urology Focus</i> , <b>2017</b> , 3, 502-509	5.1	18
139	Wnt Signaling Drives Prostate Cancer Bone Metastatic Tropism and Invasion. <i>Translational Oncology</i> , <b>2020</b> , 13, 100747	4.9	18
138	Disruptive events in the life of prostate cancer. <i>Cancer Cell</i> , <b>2011</b> , 19, 301-3	24.3	18
137	Accelerating precision medicine in metastatic prostate cancer. <i>Nature Cancer</i> , <b>2020</b> , 1, 1041-1053	15.4	18
136	Using Protein Microarrays to Study Cancer. <i>BioTechniques</i> , <b>2002</b> , 33, S46-S53	2.5	17

135	Functional and Mechanistic Interrogation of BET Bromodomain Degraders for the Treatment of Metastatic Castration-resistant Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 4038-4048	12.9	16
134	Rapid molecular assays to study human centromere genomics. <i>Genome Research</i> , <b>2017</b> , 27, 2040-2049	9.7	16
133	Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. <i>Eur Urol</i> 2010;58:12-8. <i>European Urology</i> , <b>2010</b> , 58, e29-30; author reply e31-2	10.2	16
132	Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,	11.5	16
131	Invasive squamous cell carcinomas and precursor lesions on UV-exposed epithelia demonstrate concordant genomic complexity in driver genes. <i>Modern Pathology</i> , <b>2020</b> , 33, 2280-2294	9.8	15
130	Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern India. <i>Prostate</i> , <b>2015</b> , 75, 1051-62	4.2	15
129	Next generation sequencing of extraskeletal myxoid chondrosarcoma. <i>Oncotarget</i> , <b>2017</b> , 8, 21770-21777	5.3	15
128	Heat Shock Protein Beta-1 Modifies Anterior to Posterior Purkinje Cell Vulnerability in a Mouse Model of Niemann-Pick Type C Disease. <i>PLoS Genetics</i> , <b>2016</b> , 12, e1006042	6	15
127	A proteogenomic portrait of lung squamous cell carcinoma. <i>Cell</i> , <b>2021</b> , 184, 4348-4371.e40	56.2	15
126	The enzymatic activity of apoptosis-inducing factor supports energy metabolism benefiting the growth and invasiveness of advanced prostate cancer cells. <i>Journal of Biological Chemistry</i> , <b>2012</b> , 287, 43862-75	5.4	14
125	A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: implications for precision cancer medicine. <i>Oncotarget</i> , <b>2016</b> , 7, 52888-52899	3.3	14
124	Physician Experiences and Understanding of Genomic Sequencing in Oncology. <i>Journal of Genetic Counseling</i> , <b>2018</b> , 27, 187-196	2.5	13
123	Androgen receptor activation results in metabolite signatures of an aggressive prostate cancer phenotype: an NMR-based metabolomics study. <i>Metabolomics</i> , <b>2012</b> , 8, 1026-1036	4.7	13
122	Prostate cancer biomarkers: a current perspective. <i>Expert Review of Molecular Diagnostics</i> , <b>2003</b> , 3, 459-708	5.8	13
121	Everolimus improves the efficacy of dasatinib in PDGFR-driven glioma. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 5313-5325	15.9	13
120	Role of BET proteins in castration-resistant prostate cancer. <i>Drug Discovery Today: Technologies</i> , <b>2016</b> , 19, 29-38	7.1	12
119	rSeqNP: a non-parametric approach for detecting differential expression and splicing from RNA-Seq data. <i>Bioinformatics</i> , <b>2015</b> , 31, 2222-4	7.2	11
118	Reply to Carsten Stephan, Henning Cammann, and Klaus Jung Letter to the Editor re: Scott A. Tomlins, John R. Day, Robert J. Lonigro, et al. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. <i>Eur Urol</i> . In press. <a href="http://dx.doi.org/10.1016/j.eururo.2015.04.039">http://dx.doi.org/10.1016/j.eururo.2015.04.039</a> . <i>European Urology</i> , <b>2015</b> , 68, e106	10.2	11

117	Frequent PD-L1 Protein Expression and Molecular Correlates in Urinary Bladder Squamous Cell Carcinoma. <i>European Urology</i> , <b>2018</b> , 74, 529-531	10.2	11
116	Competing for enhancers: PVT1 fine-tunes MYC expression. <i>Cell Research</i> , <b>2018</b> , 28, 785-786	24.7	11
115	Integrative Exome and Transcriptome Analysis of Conjunctival Melanoma and Its Potential Application for Personalized Therapy. <i>JAMA Ophthalmology</i> , <b>2019</b> , 137, 1444-1448	3.9	11
114	Integrating biomedical knowledge to model pathways of prostate cancer progression. <i>Cell Cycle</i> , <b>2007</b> , 6, 1177-87	4.7	11
113	DNA microarrays: implications for clinical medicine. <i>Journal of Investigative Surgery</i> , <b>2002</b> , 15, 275-9	1.2	11
112	Dynamic changes during the treatment of pancreatic cancer. <i>Oncotarget</i> , <b>2018</b> , 9, 14764-14790	3.3	11
111	An expression signature of estrogen-regulated genes predicts disease-free survival in tamoxifen-treated patients better than progesterone receptor status. <i>Transactions of the American Clinical and Climatological Association</i> , <b>2008</b> , 119, 77-90; discussion 90-2	0.9	11
110	Correlation between cribriform/intraductal prostatic adenocarcinoma and percent Gleason pattern 4 to a 22-gene genomic classifier. <i>Prostate</i> , <b>2020</b> , 80, 146-152	4.2	11
109	Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer. <i>Medical Oncology</i> , <b>2018</b> , 35, 152	3.7	11
108	Impact of tertiary Gleason pattern 5 on prostate cancer aggressiveness: Lessons From a contemporary single institution radical prostatectomy series. <i>Asian Journal of Urology</i> , <b>2015</b> , 2, 53-58	2.7	10
107	DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 5608-5622	12.9	10
106	Comprehensive Analysis of ETS Family Members in Melanoma by Fluorescence In Situ Hybridization Reveals Recurrent ETV1 Amplification. <i>Translational Oncology</i> , <b>2013</b> , 6, 405-12	4.9	10
105	Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors. <i>Translational Research</i> , <b>2017</b> , 188, 27.e1-27.e14	11	10
104	Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer.. <i>Nature</i> , <b>2021</b> ,	50.4	10
103	HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions. <i>Leukemia</i> , <b>2021</b> , 35, 3040-3043	10.7	10
102	PAX8 expression and TERT promoter mutations in the nested variant of urothelial carcinoma: a clinicopathologic study with immunohistochemical and molecular correlates. <i>Modern Pathology</i> , <b>2020</b> , 33, 1165-1171	9.8	10
101	The utility of upper urinary tract urine cytology before and after application of the Paris system. <i>Diagnostic Cytopathology</i> , <b>2019</b> , 47, 421-427	1.4	10
100	MiPanda: A Resource for Analyzing and Visualizing Next-Generation Sequencing Transcriptomics Data. <i>Neoplasia</i> , <b>2018</b> , 20, 1144-1149	6.4	10



99	An essential role for Argonaute 2 in EGFR-KRAS signaling in pancreatic cancer development. <i>Nature Communications</i> , <b>2020</b> , 11, 2817	17.4	9
98	BRAF activating mutations involving the B-II loop in V600E-negative anaplastic pleomorphic xanthoastrocytoma. <i>Acta Neuropathologica Communications</i> , <b>2018</b> , 6, 24	7.3	9
97	Clinical and morphologic review of 60 hereditary renal tumors from 30 hereditary renal cell carcinoma syndrome patients: lessons from a contemporary single institution series. <i>Medical Oncology</i> , <b>2019</b> , 36, 74	3.7	9
96	BETs abet Tam-R in ER-positive breast cancer. <i>Cell Research</i> , <b>2014</b> , 24, 899-900	24.7	9
95	Of mice and men: cancer gene discovery using comparative oncogenomics. <i>Cancer Cell</i> , <b>2006</b> , 10, 2-4	24.3	9
94	Covariate adjustment in the analysis of microarray data from clinical studies. <i>Functional and Integrative Genomics</i> , <b>2005</b> , 5, 18-27	3.8	9
93	Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?-Reply. <i>JAMA Oncology</i> , <b>2021</b> ,	13.4	9
92	Preclinical Evaluation of C-Sarcosine as a Substrate of Proton-Coupled Amino Acid Transporters and First Human Application in Prostate Cancer. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 1216-1223	8.9	8
91	Diffuse intrinsic pontine glioma-like tumor with EZHIP expression and molecular features of PFA ependymoma. <i>Acta Neuropathologica Communications</i> , <b>2020</b> , 8, 37	7.3	8
90	Genome-Wide STAT3 Binding Analysis after Histone Deacetylase Inhibition Reveals Novel Target Genes in Dendritic Cells. <i>Journal of Innate Immunity</i> , <b>2017</b> , 9, 126-144	6.9	8
89	Pathway-directed weighted testing procedures for the integrative analysis of gene expression and metabolomic data. <i>Genomics</i> , <b>2012</b> , 99, 265-74	4.3	8
88	A systems approach to model metastatic progression. <i>Cancer Research</i> , <b>2006</b> , 66, 5537-9	10.1	8
87	A caspase-resistant form of Bcl-X(L), but not wild type Bcl-X(L), promotes clonogenic survival after ionizing radiation. <i>Neoplasia</i> , <b>1999</b> , 1, 63-70	6.4	8
86	Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach. <i>Journal of Urology</i> , <b>2021</b> , 205, 732-739	2.5	8
85	Genetic diversity of NDUFV1-dependent mitochondrial complex I deficiency. <i>European Journal of Human Genetics</i> , <b>2018</b> , 26, 1582-1587	5.3	8
84	Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 555-561	7.1	7
83	Differential modulation of the androgen receptor for prostate cancer therapy depends on the DNA response element. <i>Nucleic Acids Research</i> , <b>2020</b> , 48, 4741-4755	20.1	7
82	Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry. <i>Acta Neuropathologica Communications</i> , <b>2018</b> , 6, 67	7.3	7

81	Activating mutations of the oncogene EZH2 in cutaneous melanoma revealed by next generation sequencing. <i>Human Pathology: Case Reports</i> , <b>2014</b> , 1, 21-28	0.2	7
80	The Potential of Circular RNAs as Cancer Biomarkers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2020</b> , 29, 2541-2555	4	7
79	A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 3017-3027	12.9	7
78	Clinical utility and concordance of upper urinary tract cytology and biopsy in predicting clinicopathological features of upper urinary tract urothelial carcinoma. <i>Human Pathology</i> , <b>2019</b> , 86, 76-84	3.7	7
77	Development of the CNS TAP tool for the selection of precision medicine therapies in neuro-oncology. <i>Journal of Neuro-Oncology</i> , <b>2018</b> , 137, 155-169	4.8	7
76	Clinically Integrated Sequencing Alters Therapy in Children and Young Adults With High-Risk Glial Brain Tumors. <i>JCO Precision Oncology</i> , <b>2018</b> , 2,	3.6	7
75	aBETting therapeutic resistance by Wnt signaling. <i>Cell Research</i> , <b>2015</b> , 25, 1187-8	24.7	6
74	Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy. <i>Molecular Cancer Therapeutics</i> , <b>2020</b> , 19, 2163-2174	6.1	6
73	Concurrent nuclear ERG and MYC protein overexpression defines a subset of locally advanced prostate cancer: Potential opportunities for synergistic targeted therapeutics. <i>Prostate</i> , <b>2016</b> , 76, 845-53	4.2	6
72	A subset of solitary fibrous tumors express nuclear PAX8 and PAX2: a potential diagnostic pitfall. <i>Histology and Histopathology</i> , <b>2016</b> , 31, 223-30	1.4	6
71	Characterizing the Therapeutic Potential of a Potent BET Degradar in Merkel Cell Carcinoma. <i>Neoplasia</i> , <b>2019</b> , 21, 322-330	6.4	5
70	Clinicopathologic characteristics of anterior prostate cancer (APC), including correlation with previous biopsy pathology. <i>Medical Oncology</i> , <b>2015</b> , 32, 249	3.7	5
69	Polypoidal giant cancer cells in metastatic castration-resistant prostate cancer: observations from the Michigan Legacy Tissue Program. <i>Medical Oncology</i> , <b>2020</b> , 37, 16	3.7	5
68	RNA identity crisis: hepatitis B walks the LINE. <i>Cancer Cell</i> , <b>2014</b> , 25, 259-60	24.3	5
67	Tomlins et al. reply. <i>Nature</i> , <b>2009</b> , 457, E2-E3	50.4	5
66	Diagnostic usefulness of monoclonal antibody P504S in the workup of atypical prostatic glandular proliferations. <i>American Journal of Clinical Pathology</i> , <b>2003</b> , 120, 737-45	1.9	5
65	Metastatic castration resistant prostate cancer with squamous cell, small cell, and sarcomatoid elements-a clinicopathologic and genomic sequencing-based discussion. <i>Medical Oncology</i> , <b>2019</b> , 36, 27	3.7	5
64	Clinicopathological characterisation of renal cell carcinoma in young adults: a contemporary update and review of literature. <i>Histopathology</i> , <b>2020</b> , 76, 875-887	7.3	5

63	Cancer Cell Intrinsic and Immunologic Phenotypes Determine Clinical Outcomes in Basal-like Breast Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 3079-3093	12.9	5
62	Pediatric craniopharyngioma in association with familial adenomatous polyposis. <i>Familial Cancer</i> , <b>2019</b> , 18, 327-330	3	4
61	Insights into Chinese prostate cancer with RNA-seq. <i>Cell Research</i> , <b>2012</b> , 22, 786-8	24.7	4
60	Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mouse model of prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , <b>2008</b> , 57, 1357-65	7.4	4
59	Gene-expression profiles in hereditary breast cancer. <i>Advances in Anatomic Pathology</i> , <b>2002</b> , 9, 1-6	5.1	4
58	TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma. <i>Modern Pathology</i> , <b>2021</b> , 34, 1596-1607	9.8	4
57	Immunotherapy for Conjunctival Squamous Cell Carcinoma with Orbital Extension. <i>Ophthalmology</i> , <b>2021</b> , 128, 801-804	7.3	4
56	TSLP-Driven Chromatin Remodeling and Trained Systemic Immunity after Neonatal Respiratory Viral Infection. <i>Journal of Immunology</i> , <b>2021</b> , 206, 1315-1328	5.3	4
55	Autophagy Inhibition by Targeting PIKfyve Potentiates Response to Immune Checkpoint Blockade in Prostate Cancer. <i>Nature Cancer</i> , <b>2021</b> , 2, 978-993	15.4	4
54	Molecular profiling of ETS gene rearrangements in patients with prostate cancer registered in REDEEM clinical trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 108.e5-13	2.8	3
53	Is the HERV-K HML-2 Xq21.33, an endogenous retrovirus mutated by gene conversion of chromosome X in a subset of African populations, associated with human breast cancer?. <i>Infectious Agents and Cancer</i> , <b>2020</b> , 15, 19	3.5	3
52	Mutations predictive of hyperactive Ras signaling correlate with inferior survival across high-risk pediatric acute leukemia. <i>Translational Pediatrics</i> , <b>2020</b> , 9, 43-50	4.2	3
51	Detailed pathologic analysis on the co-occurrence of non-seminomatous germ cell tumor subtypes in matched orchiectomy and retroperitoneal lymph node dissections. <i>Medical Oncology</i> , <b>2018</b> , 35, 21	3.7	3
50	Rare Presentation of Metastatic Cystic Trophoblastic Tumor in a Patient Without Prior Chemotherapy. <i>Urology Case Reports</i> , <b>2017</b> , 13, 154-157	0.5	3
49	Trisomy 12-associated, t(11;14)-negative mature B-cell leukemia with gene expression profile resembling mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2006</b> , 47, 121-7	1.9	3
48	G3BP1 inhibits Cul3 to amplify AR signaling and promote prostate cancer. <i>Nature Communications</i> , <b>2021</b> , 12, 6662	17.4	3
47	Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas. <i>Science Translational Medicine</i> , <b>2021</b> , 13, eabc0497	17.5	3
46	Case Study: Systematic Detection and Prioritization of Gene Fusions in Cancer by RNA-Seq: A DIY Toolkit. <i>Methods in Molecular Biology</i> , <b>2020</b> , 2079, 69-79	1.4	3

45	RNA-seq of human T cells after hematopoietic stem cell transplantation identifies as a regulator of T cell alloimmunity. <i>Science Translational Medicine</i> , <b>2021</b> , 13,	17.5	3
44	AGO2 promotes tumor progression in KRAS-driven mouse models of non-small cell lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,	11.5	3
43	Plasmacytoid urothelial carcinoma: a rapid autopsy case report with unique clinicopathologic and genomic profile. <i>Diagnostic Pathology</i> , <b>2019</b> , 14, 113	3	2
42	Double-Negative Prostate Cancer Masquerading as a Squamous Cancer of Unknown Primary: A Clinicopathologic and Genomic Sequencing-Based Case Study. <i>JCO Precision Oncology</i> , <b>2020</b> , 4,	3.6	2
41	Epigenetically defined therapeutic targeting in H3.3G34R/V high-grade gliomas. <i>Science Translational Medicine</i> , <b>2021</b> , 13, eabf7860	17.5	2
40	Impact of the MyProstateScore (MPS) Test on the Clinical Decision to Undergo Prostate Biopsy: Results From a Contemporary Academic Practice. <i>Urology</i> , <b>2020</b> , 145, 204-210	1.6	2
39	A novel ATXN1-DUX4 fusion expands the spectrum of CIC-rearranged sarcoma of the CNS to include non-CIC alterations. <i>Acta Neuropathologica</i> , <b>2021</b> , 141, 619-622	14.3	2
38	De novo neuroendocrine transdifferentiation in primary prostate cancer-a phenotype associated with advanced clinico-pathologic features and aggressive outcome. <i>Medical Oncology</i> , <b>2021</b> , 38, 26	3.7	2
37	Metabolism drives macrophage heterogeneity in the tumor microenvironment.. <i>Cell Reports</i> , <b>2022</b> , 39, 110609	10.6	2
36	Urothelial Cancer With Occult Bone Marrow Metastases and Isolated Thrombocytopenia. <i>Urology Case Reports</i> , <b>2015</b> , 3, 98-100	0.5	1
35	Direct cellular reprogramming enables development of viral T antigen-driven Merkel cell carcinoma in mice.. <i>Journal of Clinical Investigation</i> , <b>2022</b> ,	15.9	1
34	Integrative Next Generation Sequencing of Myeloproliferative Neoplasms and Correlation of Genetic Variations to Disease Severity. <i>Blood</i> , <b>2018</b> , 132, 4324-4324	2.2	1
33	Aneuploidy Is Associated with Inferior Survival in Relapsed Refractory Multiple Myeloma Patients. <i>Blood</i> , <b>2019</b> , 134, 4360-4360	2.2	1
32	Biochemical characterization of the interaction between KRAS and Argonaute 2.. <i>Biochemistry and Biophysics Reports</i> , <b>2022</b> , 29, 101191	2.2	1
31	TERT- beyond the territory: Usage of PCR-based TERT promoter assay in defining urothelial carcinoma in a case of long-standing prostatic adenocarcinoma. <i>Pathology Research and Practice</i> , <b>2020</b> , 216, 152663	3.4	1
30	Development of a Whole-urine, Multiplexed, Next-generation RNA-sequencing Assay for Early Detection of Aggressive Prostate Cancer. <i>European Urology Oncology</i> , <b>2021</b> ,	6.7	1
29	Association of Urinary MyProstateScore, Age, and Prostate Volume in a Longitudinal Cohort of Healthy Men: Long-term Findings from the Olmsted County Study. <i>European Urology Open Science</i> , <b>2021</b> , 29, 30-35	0.9	1
28	Clinical application of next generation sequencing in lymphoma. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 868-873	1.3	1

27	Viral Status Predicts the Patterns of Genome Methylation and Decitabine Response in Merkel Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , <b>2021</b> ,	4.3	1
26	Protein microarrays: a powerful tool to study cancer. <i>Current Opinion in Molecular Therapeutics</i> , <b>2002</b> , 4, 587-93		1
25	Defining cancer growth beyond the mitotic index.. <i>Nature Cell Biology</i> , <b>2022</b> , 24, 285-287	23.4	1
24	CRISPRs in the human genome are differentially expressed between malignant and normal adjacent to tumor tissue.. <i>Communications Biology</i> , <b>2022</b> , 5, 338	6.7	1
23	Role of Aneuploidy in Transcriptional Regulation and Clinical Prognosis in Relapsed and/or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , <b>2020</b> , 136, 45-46	2.2	0
22	Promoter Mutations in Keratinizing and Nonkeratinizing Squamous Metaplasia of the Urinary Tract.. <i>European Urology Open Science</i> , <b>2022</b> , 35, 74-78	0.9	0
21	Association of MyProstateScore (MPS) with prostate cancer grade in the radical prostatectomy specimen. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2022</b> , 40, 4.e1-4.e7	2.8	0
20	CD38 in Advanced Prostate Cancers. <i>European Urology</i> , <b>2021</b> , 79, 736-746	10.2	0
19	Germline variants discovered in lymphoma patients undergoing tumor profiling: a case series. <i>Familial Cancer</i> , <b>2021</b> , 20, 61-65	3	0
18	Comparative Molecular Analysis of Primary Central Nervous System Lymphomas and Matched Vitreoretinal Lymphomas by Vitreous Liquid Biopsy. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	0
17	Leveraging artificial intelligence to predict ERG gene fusion status in prostate cancer.. <i>BMC Cancer</i> , <b>2022</b> , 22, 494	4.8	0
16	A FIRE-y PAGE in the computational analysis of cancer profiles. <i>Molecular Cell</i> , <b>2009</b> , 36, 732-3	17.6	
15	Keystone 1997: return of the worm. Temarron, Colorado, February 18-23, 1997. <i>Cell Death and Differentiation</i> , <b>1997</b> , 4, 519-21	12.7	
14	Empirical Bayes identification [correction of identification] of tumor progression genes from microarray data. <i>Biometrical Journal</i> , <b>2007</b> , 49, 68-77	1.5	
13	TAMI-42. H3K27M MUTANT GLIOMAS HIJACK A CONSERVED AND CRITICAL METABOLIC PATHWAY USED BY IDH1 MUTANT GLIOMAS TO MAINTAIN THEIR PREFERRED EPIGENETIC STATE. <i>Neuro-Oncology</i> , <b>2020</b> , 22, ii222-ii222	1	
12	CTNI-17. CLINICAL EFFICACY AND PREDICTIVE BIOMARKERS OF ONC201 IN H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA. <i>Neuro-Oncology</i> , <b>2020</b> , 22, ii45-ii46	1	
11	Purification of an MLL Partner Associated Complex (MPAC) Suggests a Common Role for MLL Fusion Partners in Transcriptional Elongation.. <i>Blood</i> , <b>2006</b> , 108, 770-770	2.2	
10	Integrated Genomic-Transcriptomic Study Highlights Accumulation of Genetic Variants and Activation of Inflammatory Pathways. <i>Blood</i> , <b>2019</b> , 134, 4212-4212	2.2	

9	The comprehensive methylation landscape of metastatic castration-resistant prostate cancer (mCRPC) identifies new phenotypic subtypes: Results from the West Coast Prostate Cancer Dream Team (WCDT).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5507-5507	2.2
8	Genome-Wide Binding Studies of Acetyl-STAT3 Demonstrates a Novel Regulatory Pathway in Dendritic Cells. <i>Blood</i> , <b>2015</b> , 126, 647-647	2.2
7	Inhibition of Histone Methylation Arrests Ongoing Graft-Versus-Host Diseases in Mice by Selectively Inducing Apoptosis of Alloreactive Effector T Cells. <i>Blood</i> , <b>2011</b> , 118, 820-820	2.2
6	Histone Methyltransferase Ezh2 Controls T-Cell Immunity by Regulating Bioenergetic Metabolism. <i>Blood</i> , <b>2012</b> , 120, 953-953	2.2
5	The Histone Methyltransferase Ezh2 Is a Crucial Epigenetic Regulator Of Allogeneic T Cell Responses and Graft-Versus-Host Disease In Mice. <i>Blood</i> , <b>2013</b> , 122, 137-137	2.2
4	Clinical Sequencing of High-Grade Undifferentiated Sarcomas: A Case Series and Report of an Aggressive Primary Cardiac Tumor With Multiple Oncogenic Drivers. <i>JCO Precision Oncology</i> , <b>2020</b> , 4,	3.6
3	Constitutive Hedgehog/GLI2 signaling drives extracutaneous basaloid squamous cell carcinoma development and bone remodeling. <i>Carcinogenesis</i> , <b>2021</b> , 42, 1100-1109	4.6
2	PDCT-03. CLINICALLY INTEGRATED SEQUENCING IN THE MANAGEMENT OF CHILDREN WITH HIGH-RISK BRAIN TUMORS. <i>Neuro-Oncology</i> , <b>2016</b> , 18, vi145-vi146	1
1	Prostatic Adenocarcinoma With Hormone Exposure Related Changes in a Patient With Hepatic Cirrhosis - Value of Autopsy in a Case Report. <i>Urology Case Reports</i> , <b>2016</b> , 9, 37-40	0.5